A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer.

  • Jiang J
  • Liang X
  • Zhou X
 et al. 
  • 15


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


OBJECTIVE: Since the debate still exists whether cisplatin-based and carboplatin-based chemotherapy are equally effective for advanced non-small-cell lung cancer (NSCLC), a meta-analysis of trials was performed to compare the cisplatin-based with carboplatin-based regimens in first line chemotherapy of advanced NSCLC.

METHODS: A literature search was performed in PubMed database, the Cochrane Central Register of Controlled Trials (CENTRAL) database, the Physician Data Query (PDQ) database and the American Society of Clinical Oncology (ASCO) annual meeting abstracts in January 2007. The following keywords were used: "non small cell lung cancer," or "Carcinoma, Non-Small-Cell Lung". Reference lists of original articles and review articles were also examined. The published languages and years were not limited. The trials searched were evaluated for eligibility and quality, and then the data were abstracted and analyzed.

RESULTS: Eighteen randomized controlled trials (6906 patients) were identified from 4240 reports. The intention to treatment (ITT) analysis demonstrated that the cisplatin-based regimens had a higher overall response rate in comparison with carboplatin-based regimens (RR, 0.91; 95%CI, 0.84-0.99; P=0.02). However, the 1-year survival rate for the two platinum-based regimens were comparable (RR, 1.00, 95%CI, 0.94-1.07; P=0.93), Both subgroup analysis comparing the doublet or triplet regimens of cisplatin or carboplatin in combination with new agents and the same agents had achieved the same results. Cisplatin-based chemotherapy led to more frequent grade 3 or 4 of nausea and vomiting, and nephrotoxicity (OR, 0.39; 95%CI, 0.30-0.52; P
CONCLUSION: Given cisplatin-based regimens had a higher overall response rate as compared with carboplatin-based regimens, there was not a survival advantage in the cisplatin group. Therefore, the toxicity profile might play an important role in decision to choose cisplatin-based or carboplatin-based regimens.

Author-supplied keywords

  • Antineoplastic Combined Chemotherapy Protocols
  • Antineoplastic Combined Chemotherapy Protocols: ad
  • Carboplatin
  • Carboplatin: adverse effects
  • Carboplatin: therapeutic use
  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma, Non-Small-Cell Lung: drug therapy
  • Carcinoma, Non-Small-Cell Lung: mortality
  • Cisplatin
  • Cisplatin: adverse effects
  • Cisplatin: therapeutic use
  • Female
  • Humans
  • Lung Neoplasms
  • Lung Neoplasms: drug therapy
  • Lung Neoplasms: mortality
  • Male
  • Quality of Life
  • Randomized Controlled Trials as Topic
  • Treatment Outcome

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Jingwei Jiang

  • Xiaohua Liang

  • Xinli Zhou

  • Ruofan Huang

  • Zhaohui Chu

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free